Clinical Trial Detail

NCT ID NCT01808573
Title A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting (NALA)
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Puma Biotechnology, Inc.

Her2-receptor positive breast cancer


Capecitabine + Lapatinib

Capecitabine + Neratinib

Age Groups: senior adult

Additional content available in CKB BOOST